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Conclusion
In a Scottish CRC cohort and updated meta-analysis there was some evidence that statin use was associated with improved survival. However, these associations were weak in magnitude and, particularly for post-diagnosis use, varied markedly between studies.
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INTRODUCTION
It is currently estimated that there are 1.4 million incident cases of colorectal cancer (CRC) per year worldwide. 1 In the United Kingdom (UK), CRC is the second most common cause of cancer death with an associated 5-year survival of 50-55%. 2, 3 Unfortunately there have been no major advances in the treatment of locally advanced CRC since the MOSAIC study (oxaliplatin in addition to standard chemotherapy) was published over a decade ago, 4 therefore research into novel agents or novel use of existing agents is required. 5, 6 Like aspirin, statins have been identified as potential novel anti-cancer agents that are cost-effective and safe to administer. 7, 8 They inhibit the mevalonate pathway and have been shown to have anti-cancer effects in-vitro. 9 Our research group previously reported an association between both pre-and post-diagnostic statin use and improved survival in CRC using observational data. 10 However, not all observational studies assessing the role of statins in CRC survival support our findings. 8, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] A recent meta-analysis of these studies suggests the associated reduction in cancerspecific mortality was limited to pre-diagnostic statin users. 20 However two other meta-analyses conclude that the benefit is observed for both pre-and postdiagnostic statin users. 21, 22 Importantly though, none of these meta-analyses capture all of the currently available data and they all include hazard ratios for postdiagnostic statin use from one study 13 at risk of immortal time bias. 23 To clarify the association between post-diagnostic statin use and CRC survival we describe a further observational study using an independent population-based UK dataset. We also performed an updated systematic review and meta-analysis to include all additional data for post-diagnostic use that is not at risk of immortal time bias. 6 
MATERIALS AND METHODS

Cohort study
Data source
The study utilised linkages between national datasets from Scotland including the Scottish Cancer Registry (SMR06), the Prescribing Information System (available from January 2009 to January 2015), 24 the General / Acute Inpatient and Day Case dataset (SMR01), the Outpatient Attendance dataset (SMR00) and the National Records of Scotland Death Records. A more detailed description of these data resources is described in Supplementary File 1. Linkages between data sources were conducted using the Community Health Index number (unique to individuals in Scotland). The Privacy Advisory Committee of the National Health Service (NHS) National Services Scotland (NSS) approved the study.
Study population
A cohort of newly diagnosed CRC patients was identified on the basis of a Scottish Cancer Registry recorded primary diagnosis of CRC (comprising ICD codes of the colon C18 or rectum C20 including the recto-sigmoid junction C19) between January 2009 and December 2012. Cohort members with a previous Scottish Cancer Registry cancer diagnosis (after January 1999), apart from in situ neoplasms and non-melanoma skin cancers, were excluded.
As post-diagnostic medication usage is unlikely to influence survival in cases with incident metastatic disease, the analysis of medication use after diagnosis was restricted to patients with incident Dukes' A-C disease. Deaths were identified from National Records of Scotland with coverage up to 1st January 2015 (or from Scottish Cancer Registry death records) with CRC-specific deaths defined as those with underlying cause of death ICD code C18, C19, C20, C21 (anus) or C26 (other and ill-defined digestive organs). Deaths in the first year after CRC diagnosis were removed, this restriction reduces the likelihood of including patients who were not recurrence-free at exposure. 25 Patients were therefore followed from one year after CRC diagnosis to death, the date they left Scotland or 1 st January 2015, whichever occurred first.
Exposure data
Statins dispensed in the community (identified from the Prescribing Information System) consisted of all medications in the Statins section of the British National Formulary (Section 2.12). 26 A quantity of 28 tablets was assumed for the less than 0.1% of prescriptions where quantity was deemed incorrect. Daily defined doses (DDD) in each prescription were calculated by multiplying the quantity by strength (in mg) and dividing by the World Health Organization defined DDD (in mg) for individual statins as defined by the). 27 Statin use was investigated as a time-varying covariate (patients were initially considered non-users and then users after a lag of 6 months after their first statin prescription). 23 The use of a lag is recommended 25 and in this study prescriptions in the 6 month period prior to death were not considered as these may reflect end of life treatment (in sensitivity analyses the duration of this lag was varied). Dose-response analyses were conducted with individuals considered non-users prior to 6 months after first use, a short term user between 6 months after first use and 6 months after the 12 th prescription (or 365 DDDs) and a longer term user after this time.
Covariates
Data available from the Scottish Cancer Registry included Dukes' stage, histological grade and surgery, chemotherapy and radiotherapy in the six months after diagnosis. Comorbidities that contribute to the Charlson index were determined prior to diagnosis based upon ICD10 diagnosis codes, as described previously, 28 in Scottish hospital inpatient (SMR01) and outpatient data (SMR00). A deprivation measure was determined using the 2009 Scottish Index of Multiple Deprivation based upon postcode of residence. 29 Low-dose aspirin use was determined from dispensing records.
Statistical analysis
In the main analysis, time-dependent Cox regression models were used to calculate hazard ratios (HRs) for CRC-specific death and 95% confidence intervals (95% CI) for post-diagnostic statin users compared with non-users using a time-varying covariate as described previously. Deaths from other causes were censored in cancer-specific analyses. Adjusted analyses were conducted including the following potential confounders: sex, age, year of diagnosis, deprivation (in fifths), grade, site (colon or rectal), Dukes' stage, surgery (within 6 months of diagnosis), radiotherapy (within 6 months of diagnosis), chemotherapy (within 6 months of diagnosis), comorbidities (dichotomised as absent or present prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and aspirin usage (as time-varying covariate). Other commonly prescribed medications with potential anti-cancer effects (metformin, drugs affecting the reninangiotensin system and beta-blockers) were not included in the final models, as they did not alter the hazard ratio estimates. Analyses were conducted by number of prescriptions, number of DDDs and type of statin and repeated for all-cause mortality. Subgroup analyses were conducted by site (colon or rectal), stage (I-III), treatment (surgery alone versus surgery and adjuvant therapy) and finally for postdiagnostic statin users, de novo versus pre-and post-diagnostic statin use. Sensitivity analysis was conducted by increasing the lag to 1 year. A simplified analysis was also performed using Cox regression to compare statin users to nonusers in the first year after CRC diagnosis in individuals living more than 1 year after diagnosis; this controls for immortal time bias without requiring time-varying covariates. 30 Finally, an analysis was conducted based upon statin prescriptions in the year prior to diagnosis (excluding patients diagnosed in 2009 for whom a full year of prescription records prior to diagnosis may not be available), not excluding deaths in the first year after diagnosis and including all CRC patients regardless of Dukes' stage. To avoid overadjustment this analysis did not adjust for stage and grade, or restrict the cohort to Dukes' stage A to C disease, because these variables could be on the causal pathway for the association between pre-diagnostic statin use and CRC-specific mortality. 31, 32 For comparison between studies a fully adjusted model was also included. Finally, as the prevalence of commonly prescribed medications may increase in the period before cancer diagnosis an alternative definition of prediagnostic statin use in the 12-month period one to two years prior to diagnosis was also assessed (this definition requires the exclusion of patients diagnosed in 2009 and 2010).
Systematic review and meta-analysis
Search strategy
The review protocol was undertaken according to the principles recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 33 
Study selection and eligibility criteria
Two independent reviewers (R.T.G. and H.G.C.) screened all titles and abstracts to identify eligible studies. Full-text manuscripts were reviewed in cases where the title and abstract provided insufficient information to determine eligibility. Disagreements were resolved after discussion with a third party (L.J.M.). Studies were considered for inclusion if (i) they identified a cohort of CRC patients in which exposure to statin treatment was measured and recorded and (ii) they determined an estimate of progression of CRC (i.e. overall, cancer-specific, recurrence-free, progression-free or disease free survival) in a statin user group compared with non-users using measures of effect or association (HR, relative risk (RR) or odds ratio (OR)) and corresponding 95% CI, or enough information to allow these to be calculated.
Abstracts and non-English language articles were included if they met the criteria above. Authors were contacted for further information when required. Results from the current cohort study were also included in the final pooled analyses.
Data extraction and study quality assessment
Standardised data extraction forms were used to collect information on the variables listed in Supplementary File 1 (R.T.G). When the information was not clear this was discussed with a second investigator (H.G.C). The methodological quality of the studies included in the meta-analysis was assessed (R.T.G.) using the Newcastle-Ottawa scale for cohort studies 35 and the Cochrane risk of bias tool for randomised controlled trials (RCTs). 36 When the judgement of the domain was not immediately clear it was discussed with a second investigator (H.G.C. or C.R.C.).
Statistical analysis
The statistical analysis was conducted using Review Manager (RevMan [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). A random effects model was used to produce pooled estimates from the fully adjusted HRs and CIs of included studies. If these were not available estimates of the HR and standard error were produced using the indirect method proposed by Parmar et al. 37 Meta-analyses were conducted separately on statin use before and after diagnosis. Study outcomes for post-diagnostic statin use deemed to be at risk of immortal time bias, where the exposed group acquire follow-up from a fixed time point (such as diagnosis date) but do not actually commence statin therapy to later in their follow-up, were not included in the pooled analyses. 23 Between-study heterogeneity was assessed using the Cochrane Q statistic (χ 2 test) and the I 2 statistic. 38 Funnel plot asymmetry was visually assessed to determine the potential for publication bias. A number of a priori subgroup analyses were considered including tumour location (colon versus rectum), sex, age (>65 years versus ≤65 years) and disease stage. Finally, sensitivity analyses were performed by systematically removing each individual study in order to assess its effect on the pooled result estimates and accompanying heterogeneity.
RESULTS
Cohort study
Patient cohort
A total of 8,391 incident Dukes' A to C CRC cases met the inclusion criteria ( Supplementary Figure 1) , in which there was, on average, 2.4 years of exposurerelated follow-up starting one year after diagnosis (sd=1.3, minimum=0, maximum=5 years). Patient characteristics by statin use are shown in Table 1 . Statin users were more likely to be older and male. Stage and grade were generally similar by statin use, but a smaller proportion of statin users compared with statin non-users had Dukes' C disease (post-diagnostic use 32.5% versus 36.2% respectively). Statin users were more likely to have comorbidities (particularly cerebrovascular disease, diabetes and myocardial infarction) and use concomitant aspirin, but a smaller proportion received adjuvant chemotherapy.
Association between post-diagnostic statin use and survival
Overall, there was no statistically significant reduction in CRC-specific mortality when post-diagnostic statin users were compared with statin non-users (Table 2) .
Similarly, there was no evidence of a dose-response association when exposure was investigated using DDDs. The absence of an association with CRC-specific survival persisted when simvastatin was assessed and after adjustment for potential confounders. Similar results were observed for adjusted all-cause mortality in terms of marginal non-significant reductions in mortality.
Sensitivity / subgroup analyses
Sensitivity / subgroup analyses are shown in Table 3 . Stratifying by tumour location, overall mortality was reduced for post-diagnostic statin users compared to statin nonusers in patients with colon cancer (HR=0.85, 95% CI 0.74 to 0.98). However, this subgroup benefit was less apparent for CRC-specific mortality (HR=0.88, 95% CI 0.74 to 1.06). There was some evidence of reduced CRC-specific mortality for statin users compared to non-users when the analysis was restricted to stage II tumours but this was only of marginal statistical significance (HR=0.75, 95% CI 0.56 to 1.00, Supplementary Table 1 ). There was no evidence of a differential association when cases were stratified by treatment with surgery alone compared to those receiving additional adjuvant therapies ( Supplementary Table 1 ). Increasing the lag period to one year did not alter the results for post-diagnostic statin use and CRC-specific mortality (adjusted HR=0.93, 95% CI 0.79 to 1.08). Repeating the analysis using a simplified 1 year analysis also did not demonstrate a survival benefit for postdiagnostic statin use (Table 3) . When post-diagnostic statin use versus non-use was stratified by de novo compared to prior statin use, de novo post-diagnostic statin users had a more pronounced reduction in cancer-specific and overall mortality.
However, the interactions for CRC-specific and overall mortality (P for interaction=0.34 and 0.35, respectively) were not significant. Finally, in contrast to the non-significant association observed for post-diagnostic statin use, CRC-specific mortality and overall mortality were significantly improved by 16% (HR=0.84, 95%CI 0.75 to 0.94) and 11% (HR=0.89, 95% CI 0.80 to 0.98) respectively comparing prediagnostic statin users (in the year prior to diagnosis) with statin non-users. These associations were not significantly altered when the definition of pre-diagnostic use was changed to include any use in the one year period one to two years prior to diagnosis (results not shown).
Systematic review and meta-analysis
Search results and study characteristics
Fifteen studies were deemed eligible for inclusion in the final review after screening 1192 titles and abstracts ( Figure 1 ). There was one RCT, 39 six prospective population-based studies, 8, 10, 11, 16, 18, 40 two cohorts within RCTs, 12, 15 one prospective cohort within a population-based case-control study 13 and five retrospective hospitalbased cohorts (Table 4) . 14, 17, 19, 41, 42 Seven studies assessed stage I-IV disease, 11, 13, 14, [17] [18] [19] 40 three assessed stage I-III disease, 10, 16, 41 two stage III disease only, 15, 42 two stage IV disease only, 12, 39 and one did not report stage. 8 Two studies reported outcomes for only rectal cancer patients, 14, 41 one study consisted of only male subjects 17 while another related to patients with diabetes mellitus only. 18 Eleven studies reported outcomes for post-diagnostic statin use [10] [11] [12] [13] [14] [15] 18, 19, 39, 40, 42 and six reported pre-diagnostic statin use. 8, 10, 13, 16, 17, 41 The methodological quality of these 15 studies (n=14 observational, n=1 RCT) was evaluated using relevant risk of bias tools ( Supplementary Table 2 and 3 ). In addition to these studies, we also included the results from our own population-based cohort study (described above).
Post-diagnostic statin use
Four studies with 19,152 patients reported CRC-specific mortality in post-diagnostic statin users compared to statin non-users but only two of them, the current study and Cardwell et al, 10 assessed statin use as a time-varying covariate. The pooled HR was 0.84 (95% CI 0.68 to 1.04) with evidence of significant heterogeneity (heterogeneity P=0.03; I²=67%) ( Figure 2A ). Removing the study by Cardwell et al. 10 in sensitivity analysis reduced this statistical heterogeneity but moved the association closer to null ( Supplementary Table 4 ).
Twelve studies reported overall mortality in relation to post-diagnostic statin use but the HR reported by Lakha et al. 13 was excluded as it has previously been identified as being at risk of immortal time bias. 10, 20 Eleven studies (21,030 patients) were subsequently included in the pooled analysis for which the HR was 0.84 (95% CI 0.73 to 0.98). Again, there was a high level of statistical heterogeneity (heterogeneity P=0.0004; I²=69%) ( Figure 2B ). There was also methodological heterogeneity amongst the studies included in this analysis. Only four studies (the current study, Cardwell et al., 10 Voorneveld et al. 40 and Zanders et al. 18 ) assessed post-diagnostic statin use as a time-varying covariate, one considered a diabetic cohort only 18 and a further two assessed the role of statins in stage IV disease only. 12, 39 Removing individual studies in sensitivity analysis did not markedly alter the result or associated heterogeneity for overall mortality and post-diagnostic statin use (Supplementary Table 4 ).
Pre-diagnostic statin use
Six studies with 86,622 patients reported CRC-specific mortality in pre-diagnostic statin users compared to statin non-users. The pooled HR was 0.82 (95% CI 0.79 to 0.86) with no evidence of heterogeneity (heterogeneity P=0.57; I²=0%) ( Figure 3A) .
Statin exposure was determined through linkage to dispensing or prescribing databases in all of the studies included in this pooled analysis and four of the six were large population-based studies.
Six studies (44,026 patients) also reported overall mortality in relation to prediagnostic statin use. The pooled HR for overall mortality was 0.85 (95% CI 0.76 to 0.95) although there was evidence of significant heterogeneity in this analysis (heterogeneity P=0.0009; I²=76%) ( Figure 3B ). There was also greater methodological heterogeneity associated with this analysis as one study 41 relied on medical record review rather than data linkage and only three were prospective population-based cohorts (current study, Cardwell et al. 10 and Shao et al. 16 ). The heterogeneity associated with the pooled analysis for pre-diagnostic statin use and overall mortality reduced from 76% to 48% when the only study associated with increased mortality was removed ( Supplementary Table 4 ). Removing the other studies individually had no significant impact on the result or associated heterogeneity.
Subgroup analyses and publication bias
Survival estimates stratified by age, sex, stage and tumour location were not consistently reported therefore the planned subgroup analysis could not be reliably performed. Funnel plots showed no evidence of asymmetry for cancer-specific or overall mortality in pre-or post-diagnostic statin use ( Supplementary Figure 2 ).
DISCUSSION
In a large Scottish cohort of CRC patients we identified some evidence of an inverse association between CRC-specific mortality and statin use before diagnosis but less evidence of an association with statin use after diagnosis. In particular, while de novo post-diagnostic statin use was associated with reduced cancer-specific mortality in a subgroup analysis, this association was based on relatively few events and the interaction term for this stratification was not statistically significant. An updated systematic review and meta-analysis was subsequently performed which demonstrated an association with relatively small reductions in cancer-specific and all-cause mortality with statin use before and after diagnosis. However, these associations generally lacked consistency and the association between cancerspecific mortality and post-diagnostic statin use did not reach statistical significance.
We previously reported an association between improved survival outcomes and post-diagnostic statin use in a cohort of 7,657 patients within the UK National Cancer Data Repository. 10 However, despite using very similar methodology, the association with reduced mortality was smaller and non-significant in this current Scottish cohort In comparison to the results for post-diagnostic statin use, the significant association between improved survival outcomes and pre-diagnostic statin use observed in the UK National Cancer Data Repository cohort 10 persisted in the Scottish cohort study, albeit the magnitude of the effect was smaller. The subsequent pooled analysis demonstrated pre-diagnostic statin use was associated with an 18% reduction in cancer-specific mortality. The absence of statistical heterogeneity in this analysis contrasts with the other pooled analyses and could represent a more homogeneous methodological approach. In this case, the majority of studies used large-scale population-based designs and utilised prescribing or dispensing database information. Overall there were also four times as many patients in the precompared to post-diagnostic pooled analysis for cancer-specific mortality. However, the consistent association observed for pre-diagnostic users is perhaps less clinically useful, as it is difficult to intervene before diagnosis, whereas an association with post-diagnostic use could represent the potential for use as a novel adjuvant agent.
It remains unclear if the molecular phenotype of CRC developing in pre-diagnostic statin users is different to statin non-users and whether this difference conveys a survival benefit. While no benefit for statin use was identified when survival analyses were stratified by KRAS status 11, 15 or MSI, 11 the field of personalised cancer treatment is evolving and further studies should consider the molecular profile of the tumour. Additional molecular pathological epidemiology studies assessing CRC risk and progression could provide further insights into the anti-cancer effect of statins and identify potential biomarkers to tailor treatment. 45 In particular TP53 mutations, 46 immunohistochemical expression of hydroxymethylglutaryl-CoA reductase 47, 48 and single nucleotide polymorphisms in the genes which encode proteins involved in statin metabolism 48 have been identified as potential biomarkers to differentiate potentially statin sensitive tumours and warrant further study.
The strengths of the Scottish cohort study include its large population-based design and use of dispensing information with detailed information on the type, timing and dose of statins being used. One of the main limitations is that this is an observational study and there is the potential for residual confounding for which we could not control. The follow-up period was also relatively short (average 3.4 years from diagnosis with 2.4 years of follow-up) and may not be sufficient to fully assess the potential beneficial effect of statins. However, three studies included in the review have similar follow-up periods (average/median 3.4-3.8 years), 11, 18, 40 two of which demonstrated a survival benefit for post-diagnostic statin use and overall mortality. 18, 40 While dispensing information is more robust than prescribing information, compliance cannot be confirmed. Cause of death can also be misclassified when relying on data from national statistics records. 8 Healthy-user bias 49 could be responsible for the observed improvement in survival for prediagnostic users but co-morbidities were actually higher in statin users. Finally, statin users had a smaller proportion of Dukes' C cancers but the adjusted analyses should correct for this difference.
Compared to prior systematic reviews and meta-analyses, [20] [21] [22] the present updated one benefits from the ability to include data from the Scottish cohort study and at least five further studies. 19, [39] [40] [41] [42] The three previous reviews [20] [21] [22] also incorporated results from one study 13 identified as being at risk of immortal time bias, 10, 20 whereas it was excluded from our pooled analysis. In addition, the review by Zhong et al. 20 excluded the estimate reported by Nielsen et al. 8 (n=43,487 patients) for colon cancer-specific mortality and pre-diagnostic statin use despite identifying the study.
The review by Ling et al. 21 included the HR from both the nationwide cohort study and nested matched study reported by Nielsen et al. 8 adding inappropriate extra weight to this study as individuals were counted twice. Finally Ling et al. 21 and Cai et al. 22 have misclassified the HR for overall mortality reported by Siddiqui et al. 17 as cancer-specific mortality. Therefore, we believe our review adds improved rigour to prior systematic evaluations of this topic.
In summary, combining the results of this cohort study and the updated systematic review and meta-analysis suggests that statin use appears to be associated with reduced mortality in CRC. However the magnitude of the effect is weak and the association may not be causal. The association also varies markedly between studies for statin use after diagnosis, the only time point at which clinical intervention is possible. Importantly, the only RCT assessing adjuvant statin therapy after surgery for early stage colon cancer (NCT01011478) 50 has been terminated due to poor accrual (predominantly due to limited numbers of statin-naïve patients -personal communication, NSABP, 2015) . To inform the decision to conduct future trials, further observational studies reporting cancer-specific survival outcomes are therefore required to clarify the association between post-diagnostic statin use and CRC-specific survival. , comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and aspirin use (as time-varying covariate). 2 Model contains age, sex, year of diagnosis, deprivation, site (colon or rectum), stage, grade, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and aspirin use (in first year after diagnosis). 3 Excluding patients diagnosed in 2009 (who do not have complete prescription records for year before diagnosis) but not excluding patients who die within 1 year of diagnosis; adjusted model contains age, sex, year of diagnosis, deprivation, site (colon or rectum), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and aspirin use (in year prior to diagnosis). 
